CLU and Stroke: These studies suggested that increased levels of clusterin could serve as biomarkers for more severe cognitive decline, increased risk of AD, rate of AD progression, entorhinal cortex atrophy, baseline disease severity, as well as behavioural characteristics such as agitation, aggression, and decreased risk of dementia and stroke in younger non-demented participants.